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Different Effecte of Hormone Therapies on
Low-Density Lipoprotein Oxidation in
Postmenopausal Women
K.K. Koh, R. Mincemoyer, M.N. Bui, V. Guetta, R.O. Cannon, Ill. fWLB/,
N/H, Bethesda, MD, USA
Considerable experimental evidence suggests that oxidative modification of
Iowdensity Iifmprotein (LDL) is important in the psthogenesis of atheroscle-
rosis. We have previously shown that 17p-estradiol (Ez) protects LDL from
oxidation when administered to postmenopausal women (PMW). In order lo
assess the antioxidant effect of the more commonly used conjugated estro-
gen (CE) from equine sources and to assess whether coadministration of
progestin interferes with any antioxidant effect of estrogen, we administered
CE 0.625 mg daily (30 PMW)or E20.1 mg patch (20 PMW), with and without
medroxyprogesterone acetate (MPA)2.5 mg daily, each therapy for 1 month
in a randomized, crossover study. Only CE + MPA reduced LDL levels and
raised high-density lipoprotein (HDL) levels. Neither CE nor CE+MPA pro-
longed the speetrophotometric time to onset of copper-catalyzed oxidation
of LDL (LDLox): (74 + 9 to 76 * 10 rein, (p = 0.50), and 76 + 11 to 75
A 12 rein, (p = 0.59), respsdively, compared with baseline values (data =
mean + SD). Ez prolonged the time to LDLox (76 & 13 to 84 + 15 rein, p =
0.02) without inhibition of this antioxidant effect by the addition of MPA (p =
0.754). There was no correlation between effects of hormonetherapieson
LDLoxandeffectson LDLor HDLlevels.Thus,in contrast to E2,equineCE
administeredto PMWdoesnot alter LDLox,possibly due to weak in vitro
antioxidant effects of estrone, the principal estrogen of CE. Progestin did not
interfere with CE or EZeffects on LDLox. Further study is required to assess
whether the antioxidant Ez provides greater cardiovascular protection than
CE.
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m7255 The Infiuence of Serum Vitamin E on Cardiac Risk in
Patients with Advanced Coronary Disaasa: Data
from the CHAOS Triai
N. Stephens, A. Parsons, M. Mithinson, M. Brown. Northwick Park Hospital,
Harrow, UK, Cambridge UniversiM UK
Large doses of Vitamin E reduce the risk of Ml in patients with corona~
disease. This benefit is probably achieved by inhibition of the oxidation of
LDL and the stabilisation of lipid-rich coronary plaques. These doeas produca
supraphysiological levels of eerum a-tocopherol. A related and unresolved
issue is whether variations in the endogenous (ur?supp/emerrte@level of
serum a-tocopherol are of sufficient magnitude to also affect cardiac risk. We
have examined data from the Cambridge Heart Antioxidant Study (CHAOS),
a clinical trial of Vitamin E in patients with coronary disease, to address this
issue.
We studied 855 CHAOS participants on placebc. Fifty four had either
nonfatal Ml or Cardiovascular death during follow-up (median 516 days).
There was a reduction in the risk of a cardiac event from the lowest to the
highest quintile of serum a-tocopherol. The relative risk (RR) for each rise in
quintile was 0.85 (95% Cl 0.69-1.03; P = 0.09). The RR belween Ist and 5th
quintiles of serum level was 0.52 (0.21-1.28; P =0.19). This trend remained
after adjustment for cardiac risk factors and disease severity (RR for each
Wintile rise 0.83; 95% Cl 0.65-1.05; P = 0.12). Odds for each quintile, with
95% Cl, are shown.
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These data suppofl the concept that endogenous variations in the serum
antioxidant a-tocopherol are an important influence on cardiac risk.
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Eievated Cholesterol in Eldarly Survivors of Acute
Myocardial Infarction Predicts Reinfarction in the
Year after Discharge
J.E. Murillo, Y. Wang, Y.-P.Liu, H,M. Krumholz. Ya/eUniversity Schoo/ of
Medicine, New Haven, CT USA
while elevated cholesterol is a risk factor for cardiovascular disease in
middle-aged patients, the association in older age remains controversial.
To determine whether cholesterol level was a predictor of recurrent Ml
among elderly survivors with AMI, we studied 14,168 patients from the
Cooperative Cardiovascular Project cohorL These patients were hospitalized
with a principal diagnosis of AMI between June 92 and Februay 93 at one of
the 352 non-government acute care hospitals in AL, CT, 1A,and W1.Patients
with albumin <3 mg/dL or terminal illness were excluded. The final sample
comprised 5,475 patients.
After adjusting for demographic and clinical variables, other Iaboratoty
results, in-hospital procedures, and discharge medications increasing total
cholesterol level had a graded association with an increasing risk of Ml read-
mission in the year after discharge, as shown below. In subgroup analyses,
the association persisted in patients >80 yeare old.
Cholesterol(moldL) RR 950/. Cl P value
200-240 1.34 1.02-1.76 0.03
>240 1.62 1.22-2,15 <0.001
Conclusions: Among elderly survivors of AMI, an elevated cholesterol
level is associated with an increased one-year risk for reinfarction.
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\726-1 I APoPtosi~of MudePrim~rdi*in Somite~ and
Developing Muscle
H.A. Skopicki, R.C. Smith, K. Walsh. St. E/izabeth’s Mediee/ Centefi Boston,
MA, USA, Massachusetts General Hospital, Boston, MA, USA
Development of the musculoskeletal system involves myogenic determina-
tion and differentiation, While myoblast transcriptional maturation has been
well characterized, little is known about the molecular mechanisms by which
somitic cells decide between cell death and determinationfdifferentiation.
Therefore, apoptosis in somites and myoblasts was assessed in vivo by
TdT-mediated dUTP nick end labeling of mouse embryos and temporally
correlated with pro-(Bcl-XL) and anti-apoptotic (Bex, Bak) gene expression.
TUNEL labeling of embryos at days 6.0 p.c. (somites 1–7) found no
evidence of apoptosis outside of the neural tube. However, by day 9.0 p.c.,
apoptosis was present within Semites 1-3 at the rostral end. Thereafter,
apoptosis in somites proceeded rostrocaudally in relation to progressive
somitic differentiation. At day 9.5 p.c, only somites 1-6, out of the 21-26
somites present at this stage, showad evidence of apoptosis, At the level of
the forelimb bud (approximately somites 6-12) many apoptotic cells could be
seen. This persisted to at Ieastday 10.5p.c. Distal to the forelimb bud, several
somites continued to manifest apoptotic cells at their rostral end. However,
somites eaudal to aomite 18 were without evidence of apoptosis. Temporal
correlation with several pro and anti-apoptotic proteins revealed prominent
BcI-XL and Bex expression in day E9.5 p.c. somites. At days 12.5-15.5
P.c., BcI-XL expression became perinuclear. Myoblasts migrating into the
limb bud also expressed BcI-XL. Expression of BcI-XL decreased markedly
after day 14.5 p.c. The relative expression of Bex remained unchanged, This
study suggests that apoptosis is present in developing somites and is most
apparent at the level of the developing limb where it may allow formation of
the appendicular skeleton. The regulation of BcI-XL and Bax suggest their
regulatory role somitic apoptosis,
